ArticleEndocrinology, diabetes & metabolism case reports2025
Dysthyroid optic neuropathy treated with tocilizumab.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Dysthyroid optic neuropathy (DON) is the most serious complication associated with Graves' orbitopathy (GO). The primary treatment approach for DON is high-dose intravenous methylprednisolone infusion and decompression surgery. However, not all patients are suitable candidates for or can tolerate these two treatment options. Here, we present a patient diagnosed with DON in the left eye and central serous chorioretinopathy (CSC) in the right eye. Considering that glucocorticoids are contraindicated for CSC and that the patient refused orbital surgery, we opted for intravenous tocilizumab (6 doses of 8 mg/kg every 4 weeks), a monoclonal antibody against the interleukin-6 receptor. After tocilizumab infusion, the disease severity in the left eye improved from DON to moderate to severe GO, with magnetic resonance imaging showing a considerable reduction in inflammation in all affected muscles. Moreover, no adverse effects were observed in this patient. Similarly, two case reports and an observational study including nine patients with DON showed good clinical results after tocilizumab infusion, with no adverse effects having been observed. Our patient was primarily treated with tocilizumab just like one of the previous cases who had uncontrolled diabetes. Tocilizumab could potentially be considered one of the treatment options for DON patients, especially those in whom glucocorticoid therapy is inappropriate. Nonetheless, high-quality studies are warranted to verify the indications for this treatment. Learning points: Not all patients with DON are suitable candidates for or can tolerate intravenous methylprednisolone infusion. Tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has been recommended as the second-line option for patients with active moderate to severe steroid-resistant GO. Tocilizumab could potentially be considered one of the treatment options for DON patients, especially those in whom glucocorticoid therapy is inappropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.